$249.00
Manufacturer: Germany
Prevention of venous thromboembolism in adult patients who have undergone elective knee or hip replacement surgery. Prevention of strokes and systemic embolism in adult patients with non-valvular atrial fibrillation who have one or more risk factors, such as a history of stroke or transient ischemic attack, age 75 or older, hypertension, diabetes mellitus, and symptomatic heart failure (at least class II according to the new York heart Association classification). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of relapses of DVT and PE in adults (for information about patients who suffer from PE and have unstable hemodynamics, see the section “application Features”).
Description
Elicvis 5 mg. Composition
active substance: apixaban;
1 coated tablet contains 5 mg apixaban;
Elicvis 5 mg. excipients: lactose, microcrystalline cellulose, sodium croscarmellose, sodium lauryl sulfate, magnesium stearate, Opadry® II Pink (hypromellose 15 cP lactose monohydrate, titanium dioxide (E 171) triacetin; iron oxide red (E172)).
Elicvis 5 mg. Dosage form
Film-coated tablets.
Basic physical and chemical properties: pink, oval, biconvex film-coated tablets with engraving “894” on one side and “5” on the other.
Pharmacotherapeutic group
Antithrombotic drugs. Direct inhibitors of factor Xa.
ATX code B01 AF02.
Pharmacodynamics
Mechanism of action
Apixaban is a potent, reversible, direct and highly selective inhibitor of the active site of factor Xa for oral administration. For antithrombotic action, it does not need antithrombin III. Apixaban inhibits free and thrombus-related factor Xa, and also inhibits prothrombinase activity. Apixaban does not directly affect platelet aggregation, but indirectly inhibits the process of thrombin-induced platelet aggregation. By inhibiting factor Xa, apixaban prevents thrombin formation and thrombus formation. Preclinical studies of apixaban in animals showed the effectiveness of the antithrombotic action of the drug for the prevention of arterial and venous thrombosis when taken in doses that did not interfere with hemostasis processes.
Indications
Prevention of venous thromboembolism in adult patients undergoing elective knee or hip replacement surgery.
Prevention of strokes and systemic embolism in adult patients with nonvalvular atrial fibrillation who have one or more risk factors, such as a history of stroke or transient ischemic attack, age from 75 years, arterial hypertension, diabetes mellitus, symptomatic heart failure (at least class II according to the classification of the New York Heart Association).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of recurrence of DVT and PE in adults (information on patients with PE and have unstable hemodynamics is given in the section “Peculiarities of use”).
Contraindications
Hypersensitivity to the active substance or to any auxiliary component.
Clinically significant active bleeding.
Liver disease accompanied by coagulopathy and a clinically significant risk of bleeding.
Pathology or condition with a significant risk of severe bleeding (for example, existing or recent gastrointestinal ulcer disease, presence of malignant neoplasms with a high risk of bleeding, recent brain or spinal cord injury, recent brain, spinal cord or ophthalmic surgery, recent intracranial bleeding, diagnosed or suspected varicose veins of the esophagus, arteriovenous malformations, vascular aneurysms, pronounced intraspinal or intracranial vascular anomalies).
Simultaneous use of any other anticoagulants, for example unfractionated heparin, low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.), except specific cases of changes in anticoagulant therapy (see “Dosage and Administration”) or the introduction of unfractionated heparin in doses necessary to ensure the patency of the central venous or arterial catheter.
Recent Reviews